Cullinan Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held on June 12, 2025. Cullinan Therapeutics, Inc. (CGEM) is a Delaware corporation headquartered in Cambridge, Massachusetts, with common stock listed on The Nasdaq Global Select Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on four proposals at the Annual Meeting:
- Proposal One (Election of Directors): Three Class II directors were elected for three-year terms.
- Anthony Rosenberg: 47,044,236 votes for.
- David P. Ryan, M.D.: 47,241,434 votes for.
- Mary Thistle: 48,835,369 votes for.
- Proposal Two (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2025, with 51,936,984 votes for.
- Proposal Three (Say-on-Pay): The advisory vote on executive compensation was approved with 46,956,042 votes for.
- Proposal Four (Say-on-Pay Frequency): Stockholders voted to hold future executive compensation advisory votes every year. The "Every 1 Year" option received 48,458,610 votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The Board of Directors intends to hold future executive compensation advisory votes annually based on the voting results.
Key Facts for Investor Verification
- Confirmation that KPMG LLP is the appointed auditor for the fiscal year ending December 31, 2025.
- Verification of the new three-year terms for the elected Class II directors.
- Confirmation that the company will conduct annual say-on-pay votes in the future.
- Review of the total broker non-votes (3,138,175) across proposals to assess shareholder engagement levels.